Join the conversation:
About-Halozyme
About Halozyme

Helen Torley , , M.B. Ch. B., M.R.C.P. , , President, Chief Executive Officer and member of the Board of Directors

Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-US markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the US Nephrology Business Unit from 2003_ to _2009__ and the U.S. Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).

David A. Ramsay , , , Vice President, Chief Financial Officer

Mr. Ramsay joined Halozyme in 2003 as Chief Financial Officer and served in that capacity until 2009 when he was appointed Vice President, Corporate Development. After spending four years in various commercial and operational roles, Mr. Ramsay was appointed Chief Financial Officer. Prior to Halozyme, he served in various financial roles including Vice President, Chief Financial Officer of Lathian Systems. Prior to Lathian, Mr. Ramsay was Vice President, Treasurer of ICN Pharmaceuticals, now called Valeant Pharmaceuticals International, a multinational, specialty pharmaceutical company. Mr. Ramsay joined Valeant from ARCO, where he spent four years in various financial roles, most recently serving as Manager, Financial Planning & Analysis for the company’s Retail Marketing division. Prior to ARCO, he served as Vice President, Controller for Security Pacific Asian Bank, a subsidiary of Security Pacific Corporation. He began his career as an Auditor at Deloitte & Touche, where he obtained his CPA license. Mr. Ramsay received his B.S in Business Administration from the University of California, Berkeley, and his MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania.

Jean I. Liu , , M.S., J.D. , , Vice President, General Counsel

Ms. Liu joined Halozyme in 2011. Prior to Halozyme, she served as the Chief Legal Officer and Secretary of Durect Corporation (Durect) from 1998 to 2011. She has 20 years of professional experience advising pharmaceutical and biotechnology companies. Ms. Liu’s early career included work at Pillsbury, Madison & Sutro (now Pillsbury Winthrop) and the Venture Law Group where she focused on broad areas of legal advisory for early stage companies, including technology transfer, licensing, patents, and copyright and trademark litigation. During her tenure at Durect, she held a number of titled roles as the senior most legal officer, ending her tenure as Chief Legal Officer. Ms. Liu obtained her B.S. in Cellular and Molecular Biology with highest distinction from the University of Michigan at Ann Arbor, her M.S.in Biology from Stanford University, and her J.D. from Columbia University where she was a Harlan Fiske Stone Scholar.

H. Michael Shepard, Ph.D. , , , Vice President, Chief Scientific Officer

Dr. H. Michael Shepard joined the company in 2009 as Vice President, Discovery Research with extensive experience in the biotechnology industry. He was promoted to Chief Scientific Officer in December 2010. Dr. Shepard has been a founder or co-founder of several biotechnology companies and his work has included protein therapeutics (Receptor BioLogix, Inc., 2003-2008), small molecules (NewBiotics, Inc., 1997-2002), gene therapy (Canji, Inc./Schering-Plough Corporation, 1992-1997), and monoclonal antibody therapeutics (Genentech, Inc. 1980-1992). While at Genentech, Dr. Shepard participated in many of the early programs that transformed Genentech into a commercial success. Among his most important accomplishments was the description of a key mechanism by which tumor cells can escape the host immune system. This work led to the discovery of the breast cancer drug Herceptin® (trastuzumab). In 2007, Dr. Shepard shared the Warren Alpert Prize from Harvard Medical School in recognition of this achievement. Dr. Shepard received his bachelor’s degree in zoology from the University of California, Davis and his Ph.D. in Molecular, Cellular and Developmental Biology from Indiana University. Dr. Shepard was also a postdoctoral fellow at Indiana University, supported by the Damon Runyon Cancer Research Foundation.

William J. Fallon , , , Vice President, Manufacturing & Operations

Mr. William Fallon joined Halozyme in 2006 as Vice President, Manufacturing & Operations. His responsibilities include oversight of all aspects of internal and external manufacturing and facilities operations, as well as bioprocess development. Prior to Halozyme, he served as President and Chief Executive Officer of Cytovance Biologics, a contract manufacturing organization that provides manufacturing and development services to the biotechnology industry. From 2001 to 2003, he was Vice President of Technical Operations at Genzyme Corporation, having held the same position at Novazyme Pharmaceuticals, Inc. prior to its acquisition by Genzyme in 2001. Mr. Fallon joined Novazyme from Transkaryotic Therapies, where he was Vice President of Manufacturing from 1998 to 2001. From 1993 to 1998, he was employed in several management positions for the Ares-Serono Group, including Vice President, U.S. Manufacturing Operations. In this role, he served as general manager, overseeing the production and distribution of all of Serono's approved biotechnology products in the U.S. From 1990 to 1992, he was Director of Manufacturing for Centocor, Inc. His prior experience also includes various management and operational roles at Invitron Corporation and Travenol-Genentech Diagnostics. Mr. Fallon earned a B.S. in marine science and a B.A. in biology from Long Island University, and an M.S. in biology from Northeastern University.

Don A. Kennard , , , Vice President, Regulatory Affairs & Quality Assurance

Mr. Don Kennard joined Halozyme in 2004 with extensive senior management experience in the fields of regulatory affairs (RA), clinical programs, and quality assurance (QA). He has worked directly with the FDA, as well as regulatory authorities of various foreign ministries of health, to secure registration, authorize commercialization, and successfully implement quality programs, for a broad range and extensive number of product approvals across pharmaceuticals, biologics, medical devices and diagnostics. Prior to joining Halozyme, Mr. Kennard served as Vice President of Worldwide RA/QA at Quidel, Inc., a manufacturer of diagnostic products, where he led the RA/QA and clinical functions, while also establishing a Quality System CE marking program that enabled Quidel to expand and sustain sales in the European Union. From 1991 to 2001, he was Vice President of Research and Development, Regulatory Affairs, Clinical and Quality Assurance for Nobel Biocare, Inc. and Steri-Oss (acquired by Nobel Biocare). From 1981 to 1991, Mr. Kennard was Director of RA/QA at Allergan, Inc. for prescription and OTC ophthalmic and dermatological drugs, injectable drugs, biotechnology products and ophthalmic products. Prior to Allergan, he was Director of Quality Control at B. Braun. Mr. Kennard holds a B.S. in microbiology from the University of California, Long Beach.

Michael J. LaBarre , , Ph.D. , , Vice President, Product Development

Dr. Michael LaBarre joined Halozyme in 2008 and oversees all of Halozyme’s product development efforts, bringing strong expertise in chemistry, manufacturing and controls (CMC) based on his extensive experience in the biotechnology industry for both biologics and small molecules. In his previous role as Vice President of Product Development at Paramount BioSciences, LLC, Dr. LaBarre led the CMC efforts for all of the product development programs within Paramount’s portfolio. Prior to joining Paramount, Dr. LaBarre served in various research and development positions from 1995 to 2006 at Biogen Idec (previously IDEC), where he had responsibility for analytical and formulation development, protein purification, and biochemical characterization supporting numerous IND and BLA submissions, including those for Rituxan® and Zevalin®. His last position with Biogen Idec was Director of Analytical and Protein Biochemistry. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. in the analytical methods development group. He began his career at Hybritech, where he held positions in regulatory affairs and manufacturing technical support, focusing on radiolabeled antibody technologies and analytical chemistry. Dr. LaBarre received his B.S. in chemistry from Southampton College and his Ph.D. in bioinorganic chemistry from the University of Arizona.

Douglas B. Muchmore , , M.D. , , Vice President, Endocrinology Clinical Development

Dr. Douglas Muchmore joined Halozyme in 2008 with extensive expertise in clinical research trial design and implementation, the practice of endocrinology, and all stages of clinical drug development in the field of endocrinology, where he has direct experience with diabetes and osteoporosis indications. Prior to joining Halozyme, Dr. Muchmore served as Medical Fellow II on the Insulins and Devices Team and a member of the Diabetes Platform Team at Eli Lilly and Co. He acted as the key scientific developer and lead medical negotiator for FDA interactions for AIR® Insulin, Lilly’s inhaled insulin program. He was responsible for designing and executing all of the early phase studies and he successfully advanced the program to Phase 3. Dr. Muchmore’s responsibilities at Lilly also included the evaluation of promising new technologies, which is how he became aware of Halozyme’s proprietary insulin program and its recombinant human hyaluronidase enzyme technology. Dr. Muchmore served on the Evista® Product Team for osteoporosis and breast cancer indications from 1995 to 1999 and as its Physician Group Leader from 1997 to 1999. From 1982 to 1995, Dr. Muchmore was staff endocrinologist at the Scripps Clinic and Research Foundation, holding additional appointments as Clinical Assistant Professor of Medicine, University of California, San Diego, and Senior Physician, The Whittier Institute for Diabetes and Endocrinology. Dr. Muchmore received his A.B. in biological sciences from Stanford University, his M.D. from UCSD, and his internal medicine residency at the University of Washington and the University of California, Davis. Dr. Muchmore completed a Fellowship in Endocrinology and Metabolism at University Hospital, Seattle in 1982.

Joy Zhu , , M.D., Ph.D , , Vice President, Oncology Clinical Development

Dr. Joy Zhu joined Halozyme in 2011. Prior to that, from 2006 to 2011, she served as Senior Vice President of Global Clinical Development of S*BIO Pte Ltd., where she was responsible for leading all clinical and regulatory development strategies and activities. Dr. Zhu was responsible for planning and conducting all phases of clinical studies in the U.S. and around the world. Prior to joining S*BIO, she served as Senior Medical Director at Scios (J & J), and was responsible for clinical development strategies for their oncology clinical program on the west coast. In her previous leadership role at Amgen, Dr. Zhu served as Global Development Leader for the AMG 162 (denosumab) oncology program, demonstrating significant leadership in development strategies and executing global Phase 2 and 3 oncology studies, which led to the approval of XGEVA™, for the prevention of skeletal-related events (SREs) from solid tumors. At Sugen (Pfizer), she made significant contributions to the approval of Sutent® indicated for renal cell carcinoma. At Novartis, she worked on two successful NDA submissions leading to the approval of Zaditor® and Rescula®. Dr. Zhu received her M.D. from Beijing Medical University and herPh.D. in Biochemistry from Georgia Institute of Technology.